vs
Side-by-side financial comparison of Future Vision II Acquisition Corp. (FVN) and Prime Medicine, Inc. (PRME). Click either name above to swap in a different company.
Prime Medicine, Inc. is the larger business by last-quarter revenue ($838.0K vs $584.4K, roughly 1.4× Future Vision II Acquisition Corp.). Future Vision II Acquisition Corp. runs the higher net margin — 86.8% vs -5498.7%, a 5585.5% gap on every dollar of revenue.
Future Vision II Acquisition Corp is a special purpose acquisition company formed to pursue mergers, asset acquisitions, or business combinations with high-growth enterprises. It targets technology, consumer, and sustainable industry segments across North American and Asia-Pacific markets to drive long-term shareholder value.
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
FVN vs PRME — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $584.4K | $838.0K |
| Net Profit | $507.0K | $-46.1M |
| Gross Margin | — | — |
| Operating Margin | -14.4% | -5800.5% |
| Net Margin | 86.8% | -5498.7% |
| Revenue YoY | — | -61.6% |
| Net Profit YoY | — | -9.0% |
| EPS (diluted) | — | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $584.4K | $838.0K | ||
| Q3 25 | $618.7K | $1.2M | ||
| Q2 25 | $614.4K | $1.1M | ||
| Q1 25 | $612.4K | $1.5M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $147.8K | — | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $591.0K |
| Q4 25 | $507.0K | $-46.1M | ||
| Q3 25 | $557.2K | $-50.6M | ||
| Q2 25 | $551.9K | $-52.6M | ||
| Q1 25 | $454.3K | $-51.9M | ||
| Q4 24 | — | $-42.3M | ||
| Q3 24 | $141.9K | — | ||
| Q2 24 | — | $-55.3M | ||
| Q1 24 | — | $-45.8M |
| Q4 25 | -14.4% | -5800.5% | ||
| Q3 25 | -11.2% | -4406.0% | ||
| Q2 25 | -11.5% | -4787.2% | ||
| Q1 25 | -27.3% | -3603.3% | ||
| Q4 24 | — | -2025.7% | ||
| Q3 24 | -4.5% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -8179.5% |
| Q4 25 | 86.8% | -5498.7% | ||
| Q3 25 | 90.1% | -4129.1% | ||
| Q2 25 | 89.8% | -4716.7% | ||
| Q1 25 | 74.2% | -3568.8% | ||
| Q4 24 | — | -1936.6% | ||
| Q3 24 | 96.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -7743.0% |
| Q4 25 | — | $-0.22 | ||
| Q3 25 | — | $-0.32 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.40 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-0.46 | ||
| Q1 24 | — | $-0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $61.0M | $63.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.8M | $120.9M |
| Total Assets | $62.1M | $342.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $61.0M | $63.0M | ||
| Q3 25 | — | $71.4M | ||
| Q2 25 | — | $53.8M | ||
| Q1 25 | — | $91.9M | ||
| Q4 24 | — | $182.5M | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | — | $55.6M | ||
| Q1 24 | — | $94.2M |
| Q4 25 | $1.8M | $120.9M | ||
| Q3 25 | $3.1M | $161.8M | ||
| Q2 25 | $4.3M | $60.9M | ||
| Q1 25 | $7.0M | $106.9M | ||
| Q4 24 | — | $153.1M | ||
| Q3 24 | $6.7M | — | ||
| Q2 24 | — | $196.6M | ||
| Q1 24 | — | $243.8M |
| Q4 25 | $62.1M | $342.7M | ||
| Q3 25 | $61.6M | $385.0M | ||
| Q2 25 | $61.0M | $279.0M | ||
| Q1 25 | $60.4M | $328.2M | ||
| Q4 24 | — | $297.5M | ||
| Q3 24 | $59.4M | — | ||
| Q2 24 | — | $259.7M | ||
| Q1 24 | — | $311.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-99.4K | $-37.3M |
| Free Cash FlowOCF − Capex | — | $-37.5M |
| FCF MarginFCF / Revenue | — | -4480.4% |
| Capex IntensityCapex / Revenue | — | 34.6% |
| Cash ConversionOCF / Net Profit | -0.20× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-167.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-99.4K | $-37.3M | ||
| Q3 25 | $-7.1K | $-35.0M | ||
| Q2 25 | $-11.2K | $-41.4M | ||
| Q1 25 | $-190.1K | $-48.9M | ||
| Q4 24 | — | $16.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-67.7M |
| Q4 25 | — | $-37.5M | ||
| Q3 25 | — | $-35.3M | ||
| Q2 25 | — | $-43.0M | ||
| Q1 25 | — | $-51.3M | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-47.4M | ||
| Q1 24 | — | $-70.0M |
| Q4 25 | — | -4480.4% | ||
| Q3 25 | — | -2880.5% | ||
| Q2 25 | — | -3855.1% | ||
| Q1 25 | — | -3526.8% | ||
| Q4 24 | — | 662.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -11849.6% |
| Q4 25 | — | 34.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 141.0% | ||
| Q1 25 | — | 166.6% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 393.2% |
| Q4 25 | -0.20× | — | ||
| Q3 25 | -0.01× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | -0.42× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
